157 related articles for article (PubMed ID: 38551778)
1. Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain.
Iriuchishima H; Saito A; Mihara M; Terasaki Y; Matsumoto A; Isoda A; Furukawa Y; Matsumoto M
Int J Hematol; 2024 Mar; ():. PubMed ID: 38551778
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
3. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
4. The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
Gao L; Liu Y; Li Y; Feng L; Wang Z; Wen L; Wang F; Huang X; Lu J; Lai Y
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):535-544. PubMed ID: 35292207
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Mohan M; Weinhold N; Schinke C; Thanedrarajan S; Rasche L; Sawyer JR; Tian E; van Rhee F; Zangari M
Br J Haematol; 2020 Apr; 189(1):67-71. PubMed ID: 31820442
[TBL] [Abstract][Full Text] [Related]
6. The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients.
You H; Jin S; Wu C; Wang Q; Yan S; Yao W; Shi X; Shang J; Yan L; Yao Y; Wang J; Wang P; Pan J; Wu D; Fu C
Front Oncol; 2022; 12():938392. PubMed ID: 36276097
[TBL] [Abstract][Full Text] [Related]
7. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
Facon T; Moreau P; Špicka I; Suzuki K; Yong K; Mikhael J; Fukao T; Bisht K; Armstrong NM; Macé S; Risse ML; Martin T
Hematol Oncol; 2024 Mar; 42(2):e3258. PubMed ID: 38402467
[TBL] [Abstract][Full Text] [Related]
8. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review.
Tang W; Zhang L; Zheng Y; Pan L; Niu T
Front Oncol; 2024; 14():1286029. PubMed ID: 38333688
[TBL] [Abstract][Full Text] [Related]
10. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens.
Liu X; Jia S; Chu Y; Tian B; Gao Y; Zhang C; Zheng Y; Jia W; Liu X; Yuan R; Zhang N; Feng J; Dong H; Xin X; Chang Z; Cao Z; Tang H; Gao G
Front Oncol; 2022; 12():938550. PubMed ID: 36185185
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
Nahi H; Våtsveen TK; Lund J; Heeg BM; Preiss B; Alici E; Møller MB; Wader KF; Møller HE; Grøseth LA; Østergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
Eur J Haematol; 2016 Jan; 96(1):46-54. PubMed ID: 25779478
[TBL] [Abstract][Full Text] [Related]
13. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population.
Yu W; Guo R; Qu X; Qiu H; Li J; Zhang R; Chen L
Onco Targets Ther; 2016; 9():295-302. PubMed ID: 26834489
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Jakubowiak AJ; Kumar S; Medhekar R; Pei H; Lefebvre P; Kaila S; He J; Lafeuille MH; Cortoos A; Londhe A; Mavros P; Lin TS; Usmani SZ
Oncologist; 2022 Jul; 27(7):e589-e596. PubMed ID: 35462406
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab in untreated newly diagnosed multiple myeloma.
Abdallah N; Kumar SK
Ther Adv Hematol; 2019; 10():2040620719894871. PubMed ID: 31903177
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.
Giri S; Grimshaw A; Bal S; Godby K; Kharel P; Djulbegovic B; Dimopoulos MA; Facon T; Usmani SZ; Mateos MV; Costa LJ
JAMA Oncol; 2020 Nov; 6(11):1759-1765. PubMed ID: 32970151
[TBL] [Abstract][Full Text] [Related]
17. Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.
Chen H; Zhou N; Shi H; Yu W; Wu L; Zhou F
Hematology; 2023 Dec; 28(1):2177979. PubMed ID: 36794720
[TBL] [Abstract][Full Text] [Related]
18. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
19. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Guman T; Sykora J
Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies.
Bisht K; Walker B; Kumar SK; Spicka I; Moreau P; Martin T; Costa LJ; Richter J; Fukao T; Macé S; van de Velde H
Expert Rev Hematol; 2021 Dec; 14(12):1099-1114. PubMed ID: 34551651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]